223 related articles for article (PubMed ID: 24050506)
21. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
Tsimberidou AM; Catovsky D; Schlette E; O'Brien S; Wierda WG; Kantarjian H; Garcia-Manero G; Wen S; Do KA; Lerner S; Keating MJ
Cancer; 2006 Jul; 107(1):125-35. PubMed ID: 16700034
[TBL] [Abstract][Full Text] [Related]
22. Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma.
Gebhart J; Lechner K; Skrabs C; Sliwa T; Müldür E; Ludwig H; Nösslinger T; Vanura K; Stamatopoulos K; Simonitsch-Klupp I; Chott A; Quehenberger P; Mitterbauer-Hohendanner G; Pabinger I; Jäger U; Geissler K
Thromb Res; 2014 Nov; 134(5):980-4. PubMed ID: 25201005
[TBL] [Abstract][Full Text] [Related]
23. [Splenic marginal zone lymphoma].
Mohamed S
Pan Afr Med J; 2017; 26():111. PubMed ID: 28533834
[TBL] [Abstract][Full Text] [Related]
24. Splenectomy with chemotherapy vs surgery alone as initial treatment for splenic marginal zone lymphoma.
Milosevic R; Todorovic M; Balint B; Jevtic M; Krstic M; Ristanovic E; Antonijevic N; Pavlovic M; Perunicic M; Petrovic M; Mihaljevic B
World J Gastroenterol; 2009 Aug; 15(32):4009-15. PubMed ID: 19705496
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base.
Fallah J; Olszewski AJ
Hematology; 2019 Dec; 24(1):378-386. PubMed ID: 30885066
[TBL] [Abstract][Full Text] [Related]
26. Risk-tailored treatment of splenic marginal zone lymphoma.
Castelli R; Balzarotti M; Salvi E; Simona Rossi R; Lambertenghi Deliliers G; Bergamaschini L; Gidaro A
Anticancer Drugs; 2022 Jan; 33(1):e36-e42. PubMed ID: 34407041
[TBL] [Abstract][Full Text] [Related]
27. Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes.
Iannitto E; Minardi V; Calvaruso G; Ammatuna E; Florena AM; Mulè A; Tripodo C; Quintini G; Abbadessa V
Eur J Haematol; 2005 Aug; 75(2):130-5. PubMed ID: 16000129
[TBL] [Abstract][Full Text] [Related]
28. Splenic marginal zone lymphoma: current knowledge and future directions.
Thieblemont C; Davi F; Noguera ME; Brière J; Bertoni F; Zucca E; Traverse-Glehen A; Felman P; Berger F; Salles G; Coiffier B
Oncology (Williston Park); 2012 Feb; 26(2):194-202. PubMed ID: 22489356
[TBL] [Abstract][Full Text] [Related]
29. Surgical management of splenic marginal zone lymphoma.
Kennedy ND; Lê GN; Kelly ME; Harding T; Fadalla K; Winter DC
Ir J Med Sci; 2018 May; 187(2):343-347. PubMed ID: 29043543
[TBL] [Abstract][Full Text] [Related]
30. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma.
Else M; Marín-Niebla A; de la Cruz F; Batty P; Ríos E; Dearden CE; Catovsky D; Matutes E
Br J Haematol; 2012 Nov; 159(3):322-8. PubMed ID: 23016878
[TBL] [Abstract][Full Text] [Related]
31. Splenic marginal zone B-cell lymphoma: a distinct clinicopathological and molecular entity. Recent advances in ontogeny and classification.
Traverse-Glehen A; Baseggio L; Salles G; Felman P; Berger F
Curr Opin Oncol; 2011 Sep; 23(5):441-8. PubMed ID: 21760505
[TBL] [Abstract][Full Text] [Related]
32. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.
Thieblemont C; Felman P; Berger F; Dumontet C; Arnaud P; Hequet O; Arcache J; Callet-Bauchu E; Salles G; Coiffier B
Clin Lymphoma; 2002 Jun; 3(1):41-7. PubMed ID: 12141954
[TBL] [Abstract][Full Text] [Related]
33. Results of Upfront Therapy for Marginal Zone Lymphoma.
Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
[TBL] [Abstract][Full Text] [Related]
34. Time Trend Analysis of Splenectomy for Splenic Marginal Zone Lymphoma: Declining Surgery, Promising Survival.
Yang Z; Liu L; Leng K; Shi G
Ann Surg Oncol; 2023 Nov; 30(12):7206-7216. PubMed ID: 37516724
[TBL] [Abstract][Full Text] [Related]
35. Rituximab monotherapy for splenic marginal zone lymphoma with villous lymphocytes: report on long-term disease control for two patients with recurrence after splenectomy.
Debiasi M; Hehnemann M; Garicochea B
Sao Paulo Med J; 2010 Dec; 128(6):375-7. PubMed ID: 21308163
[TBL] [Abstract][Full Text] [Related]
36. Clinical Characteristics, Treatment and Evolution of Splenic and Nodal Marginal Zone Lymphomas-Retrospective and Multicentric Analysis of Portuguese Centers.
Rodrigues CD; Peixeiro RP; Viegas D; Chorão P; Couto ME; Gaspar CL; Fernandes JP; Alves D; Ribeiro LA; de Vasconcelos M P; Tomé AL; Badior M; Coelho H; Príncipe F; Chacim S; da Silva MG; Coutinho R
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e839-e844. PubMed ID: 34326035
[TBL] [Abstract][Full Text] [Related]
37. Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden.
Sima A; Hollander P; Baecklund E; Smedby KE; Enblad G; Amini RM
Br J Haematol; 2021 Aug; 194(3):568-579. PubMed ID: 34109612
[TBL] [Abstract][Full Text] [Related]
38. How to treat splenic marginal zone lymphoma (SMZL) in patients unfit for surgery or more aggressive therapies: experience in 30 cases.
Cervetti G; Ghio F; Cecconi N; Morganti R; Galimberti S; Petrini M
J Chemother; 2017 Apr; 29(2):126-129. PubMed ID: 27454143
[TBL] [Abstract][Full Text] [Related]
39. Splenic marginal zone lymphoma: a case report and literature review.
Zhang S; Xuan Z; Zhang L; Lu J; Song P; Zheng S
World J Surg Oncol; 2020 Oct; 18(1):259. PubMed ID: 33004051
[TBL] [Abstract][Full Text] [Related]
40. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
Castelli R; Bergamaschini L; Deliliers GL
Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
